Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 3/20 | 0.30 |
| ▸ | BTK | Q06187 | 3/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24457824 | 0.85 | LPL (0.36) | LPLLIPGJAK2BTK | |
| SCHEMBL14852840 | 0.83 | LPL (0.33) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL190545 | 0.80 | LPL (0.40) | LPLLIPGCD44JAK2BTK | |
| SCHEMBL29842912 | 0.80 | LPL (0.40) | LPLLIPGCD44JAK2BTK | |
| SCHEMBL18133829 | 0.80 | JAK2 (0.40) | LPLLIPGJAK2BTK | |
| SCHEMBL106624 | 0.80 | LPL (0.31) | LPLLIPG | |
| SCHEMBL168780 | 0.78 | LPL (0.46) | LPLLIPGCD44CA1CA2 | |
| SCHEMBL31380588 | 0.78 | LPL (0.46) | LPLLIPGCD44CA1CA2 | |
| SCHEMBL29470921 | 0.78 | LPL (0.36) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL29503402 | 0.77 | CYP3A4 (0.46) | LPLLIPGCD44JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822457-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822457-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ROCHE PALO ALTO LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ROCHE PALO ALTO LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8426409-B2 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES (HK) | 2012-05-24 | — | — | US | disclosed |
| US-8124604-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2011-05-05 | — | — | US | disclosed |
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | LPL 3751/4885LIPG 2990/4885CD44 4501/4885 |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | BTK, LCK, SYK | LPL 4125/4885LIPG 3650/4885CD44 4529/4885 |
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | LPL 3751/4885LIPG 2990/4885CD44 4501/4885 |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | LPL 3751/4885LIPG 2990/4885CD44 4501/4885 |
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | BTK, LCK, LYN | LPL 3251/4885LIPG 2799/4885CD44 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.